VIBERZI(TM) (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine

VIBERZI has been approved for use in the United States in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D) VIBERZI demonstrated effective and sustained relief of abdominal pain and diarrhea IBS-D can be debilitating, affecti... Biopharmaceuticals, GastroenterologyAllergan, VIBERZI, irritable bowel syndrome, IBS-D
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news